Marshall Wace
IMDX

Marshall Wace’s Insight Molecular Diagnostics IMDX Stock Holding History

Marshall Wace’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,161
Closed -$225K – 4174
2021
Q3 		$225K Sell
3,161
-3,775
-54% -$347K ﹤0.01% 2762
2021
Q2 		$796K Sell
6,936
-10,998
-61% -$1.07M ﹤0.01% 1922
2021
Q1 		$1.86M Buy
17,934
+17,143
+2,167% +$1.63M 0.01% 1363
2020
Q4 		$38K Buy
+791
New +$29K ﹤0.01% 1819
2019
Q2 		– Sell
-198
Closed -$16K – 1695
2019
Q1 		$16K Buy
+198
New +$12.8K ﹤0.01% 1638

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Marshall Wace's IMDX Position: Q4 2021 in Review

Marshall Wace sold out of Insight Molecular Diagnostics (IMDX) in Q4 2021, closing a stake of 3,161 shares — an estimated $225K sold.

Marshall Wace first reported a position in IMDX in Q1 2019 and held it in 5 quarters. The position peaked at $1.86M in Q1 2021. 88 funds tracked by Wall St. Rank hold IMDX as of Q4 2021.

  • Marshall Wace reported no remaining Insight Molecular Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Marshall Wace sold 3,161 Insight Molecular Diagnostics shares in Q4 2021, an estimated $225K.
  • Marshall Wace first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 5 quarters.
  • Marshall Wace's Insight Molecular Diagnostics position peaked at $1.86M in Q1 2021.
  • 88 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.